Meridian Bioscience, Inc. (VIVO) Misses Q4 EPS by 2c; Reaffirms FY12 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Join SI Premium – FREE
Meridian Bioscience, Inc. (NASDAQ: VIVO) reported Q4 EPS of $0.17, $0.02 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $40.27 million versus the consensus estimate of $43.29 million.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Reaffirms FY12 outlook.
For earnings history and earnings-related data on Meridian Bioscience, Inc. (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Johnson Controls (JCI) Tops Q4 EPS by 1c; offers guidance
- PayPal (PYPL) Tops Q3 EPS by 14c; lifts EPS guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
